The Competition Commission of South Africa, is investigating the price of US pharmaceutical manufacturer Gilead Science’s coronavirus treatment remdesivir and prices charged by generic firms to which it granted manufacturing license after a complaint by activists and researchers.
Commission spokesperson Makunga Siyabulela said on Monday, August 31, that the organization received a request from non-profit organisation the Health Justice Initiative (HJI) and Wits research unit Ezintsha to examine the price of remdesivir. “It is … currently under investigation and remedies are likely to be behavioural and/or an administrative penalty, if there is a finding of a contravention,” he said.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI